RNTX vs RFIL Comparison

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

RF Industries Ltd is engaged in the design, manufacture, and marketing of interconnect products and systems, including coaxial and specialty cables, fiber optic cables and connectors, and electrical and electronic specialty cables. The company operates through two segments: RF Connector and Cable Assembly, which consists of the Connector and Cable Assembly Division, and Custom Cabling Manufacturing and Assembly, which consists of its subsidiaries. Connector segment designs, manufactures, markets and distributes a broad range of RF connector, adapter, coupler, divider, and cable products etc. The Custom Cabling segment custom copper and fiber cable assemblies etc. The company operates in Canada, Italy, China, USA, UK.